Page 3 - Bharat Biotech

Govt approves Bharat Biotech's intranasal Covid-19 vaccine as booster

Bharat Biotech's intranasal Covid vaccine has been approved by the Union Health Ministry as a booster dose for those aged 18 years and above and is likely to be introduced on the Co-WIN platform Friday evening, official sources said. The needle-free vaccine will be available at private hospitals as of now and can be administered as a precaution dose to adults who have been vaccinated with two doses of either Covishield or Covaxin. It is likely to be rolled out in the national Covid vaccination programme soon, they said. The ministry's approval for the intranasal vaccine as a booster comes amid a spurt in Covid cases in China and some other countries. The nasal vaccine -- BBV154 -- had received approval of the Drugs Controller General of India (DCGI) in November for restricted use in an emergency situation for those above 18 years as a heterologous booster dose. "The vaccine branded as iNCOVACC is likely to be introduced on the Co-WIN platform Friday evening onwards. For now, it wi

Covid-19: Bharat Biotech's nasal vaccine gets govt nod as booster shot

The approval for the vaccine comes amid a spurt in Covid cases in China and some other countries

Bharat Biotech urges Centre to include intranasal Covid vaccine in CoWIN

: Bharat Biotech has requested the central government to include its intranasal COVID-19 vaccine iNCOVACC, in CoWIN portal to enable the recipients of the jab to get vaccination certificate. The company sources said Bharat Biotech is currently holding discussions with international potential partners who have approached the company for manufacturing and distribution of the intranasal vaccine globally. Since iNCOVACC has been approved for Restricted use under emergency situation and vaccine recipients will require vaccine certificates, we have requested the government to include iNCOVACC in the COWIN portal. Once this is enabled, India will be one of the few countries to have introduced an intranasal vaccine in its immunization program against COVID, the sources told PTI. Currently Bharat Biotech's Covaxin, Serum Institute's Covishield and Covovax, Russian Sputink V and Biological E Ltd's Corbevax are listed in the CoWin portal. The vaccine maker on September 6 announced that its ..

CCI approves Bharat Biotech International-Eastman exports deal

The Competition Commission of India on Monday said it has approved the proposed deal of Bharat Biotech International Ltd for acquiring shares of Eastman Exports Global Clothing Pvt Ltd through a share purchase agreement. The deal has been approved under the green channel route, wherein a transaction which does not raise any risk of an appreciable adverse effect on competition is deemed to be approved on it being intimated to the competition watchdog. In a release on the CCI's website, the fair trade regulator said it has approved the deal. The proposed combination relates to the acquisition of shares of Eastman Exports Global Clothing (EEGC) by Bharat Biotech International Ltd (BBIL) being implemented by way of the share subscription agreement, share purchase agreement. "Given that there are no horizontal overlaps, vertical and/or complementary links between the activities of the BBIL (including its affiliates) and EEGC, the proposed combination is being notified under the green .

Bharat Bio looks for partners to manufacture, distribute iNCOVACC globally

Its local production ramp-up remains unhurried as demand for boosters reduces

Bharat Biotech gets nasal vaccine nod for use as mix-match booster

iNCOVACC first intranasal Covid shot to receive approval for primary 2-dose schedule, heterologous booster us

Bharat Biotech's Intranasal Covid booster gets DCGI nod for restricted use

As per the vaccine manufacturer, the nasal route has excellent potential for vaccination due to the organised immune systems of the nasal mucosa

Biotech firm Bharat Serums & Vaccines working to reduce import dependence

Firm is develop recombinant products in hormones, eyes acquisitions in South East Asia

PLI schemes should focus on firms making pharma products: Bharat Biotech

Production-linked incentive schemes should also focus on companies providing packaging materials and other services in addition to manufacturers of branded pharmaceutical items to reduce import dependence, according to Bharat Biotech Executive Director Sai Prasad. He also emphasised on shifting the focus towards innovative pharmaceuticals products in order to enhance the margins for industry players. "We already have policies like production-linked incentive (PLI) schemes and research-based schemes and these policies are going to be very helpful for the sector... It is our view that such policies should also focus on companies which provide goods and services to the pharma industry," Prasad told PTI in an interaction. The incentives also need to be given to single-use consumer companies, raw material packaging firms and other service providers in the pharmaceutical supply chain, he added. "If the ecosystem is strong only then the branded companies could be strong," Prasad said. He

Nasal vaccines for Covid-19: How do they work and what are their benefits?

The Drugs Controller General of India (DCGI), on Tuesday, approved Bharat Biotech's anti-covid vaccine for emergency use. It is the first such vaccine in the country

DCGI nod sought for phase-3 study of intranasal Covid vax in 5-18 age group

Hyderabad-based firm Bharat Biotech has sought permission from the drug regulator to conduct phase-3 study of its intranasal COVID-19 vaccine in the 5 to 18 age group. On September 6, the Drugs Controller General of India (DCGI) had approved its intranasal Covid vaccine iNCOVACC for restricted emergency use in those aged above 18 years. "Now the Hyderabad based firm has submitted an application seeking permission to conduct phase-3, multicenter study to evaluate the safety, reactogenicity and immunogenicity of iNCOVACC (BBV154) in those aged 18 to 5 years," an official source told PTI. iNCOVACC is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised spike protein. This vaccine candidate was evaluated in phase 1, 2 and 3 clinical trials with successful results, a release from the vaccine-maker said. BBV154 has been specifically formulated to allow intranasal delivery. "Being an intranasal vaccine, BBV154 may produce local antibodies in the up

Bharat Biotech awaits booster dose nod for intranasal vaccine iNCOVACC

Bharat Biotech did not comment on its plans to make this vaccine available for young children

LIVE: Union Cabinet approves policy on long-term leasing of Railways' land

300 cargo terminals will be developed in 5 years, says Union Minister Anurag Thakur on Union Cabinet decisions

India's first nasal vaccine for Covid-19 gets DCGI nod for emergency use

Bharat Biotech's iNCOVACC cleared for 2-dose regimen

Intranasal Covid vaccine will be global game changer: Bharat Biotech MD

Phase III trials were conducted for safety, and immunogenicity in about 3,100 subjects, in 14 trial sites across India

Bharat Biotech's intranasal Covid vaccine gets DCGI's nod for emergency use

The Drugs Controller General of India (DCGI) on Tuesday approved Bharat Biotech's intranasal Covid vaccine for restricted emergency use in those aged above 18 years. "Big Boost to India's Fight Against COVID-19! Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation," Union Health Minister Mansukh Mandaviya tweeted. He said this step will further strengthen "our collective fight" against the pandemic. India has harnessed its science, research and development (R&D), and human resources in the fight against COVID-19 under Prime Minister Narendra Modi's leadership, he said. "With the science-driven approach & Sabka Prayas, we will defeat COVID-19," Mandaviya also said. The Hyderabad-based firm completed clinical trials of the nasal vaccine with about 4,000 volunteers and there is no side effect or adverse

Fight against Covid-19: Here is a list of vaccines approved in India

Besides Bharat Biotech's nasal vaccine, India has 13 vaccines to fight against Covid-19. Two have been approved for manufacturing, while 11 have been approved for emergency use

Bharat Biotech says Phase 3 trial over, intranasal vaccine 'safe'

The Hyderabad-based company claimed that BBV154 is proven to be safe, well-tolerated and immunogenic in the subjects under controlled clinical trials

Top headlines: Ola Electric to produce EVs in 2024; SBI hikes MCLR

SBI's overnight, one-month, and three-month MCLR stands at 7.35 per cent; six-month is at 7.65 per cent; one-year at 7.70 per cent; two-year at 7.90 per cent; and three-year MCLR stands at 8 per cent

Covid intranasal vaccine Phase III trials over, proven safe: Bharat Biotech

BBV154 was developed in partnership with Washington Univ St Louis, which had designed and developed recombinant adenoviral vectored constructs and evaluated them in preclinical studies for efficacy